Alk-positive Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Alk-positive Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) [Phase 1]
Phase 1 study evaluating gilteritinib in adults with advanced ALK-positive non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating TRI-611 for ALK-positive non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors
This update announces the availability of an Expanded Access Program for Neladalkib (NVL-655) for patients with advanced ALK-positive non-sm…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
A post-marketing surveillance study of Lorviqua (lorlatinib) in Korea for metastatic ALK-positive non-small cell lung cancer is currently re…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context [NA]
A clinical trial update announcing the ongoing recruitment of a real-world study evaluating lorlatinib in untreated ALK-positive non-small c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC [Phase 3]
A Phase 3 trial of neladalkib (NVL-655) for tyrosine kinase inhibitor–naive patients with advanced ALK-positive non-small cell lung cancer i…
-
CLINICAL_TRIALS research · 2025-06-12Clinical Trial Update: Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer [Phase 2]
A phase 2 neoadjuvant trial of WX-0593 for resectable ALK-positive or ROS1-positive non-small cell lung cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-02-26Clinical Trial Update: ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study
A multi-institution retrospective study evaluating digital pathology outcome prediction in ALK-positive non-small cell lung cancer treated w…
-
CLINICAL_TRIALS trial_result · 2025-02-25Clinical Trial Update: Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC [Phase 2]
Phase 2 clinical trial update evaluating chemotherapy combined with immune checkpoint inhibitors in ALK-rearranged non-small cell lung cance…
-
CLINICAL_TRIALS research · 2024-10-22Clinical Trial Update: The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study
A real-world study is being conducted to determine the incidence and risk factors of CNS adverse events in ALK-positive advanced non-small c…
-
CLINICAL_TRIALS trial_result · 2024-10-16Clinical Trial Update: Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Post-market surveillance clinical trial evaluating ALK-positive advanced non-small cell lung cancer patients treated with Iruplinalkib; the …
-
CLINICAL_TRIALS research · 2024-05-13Clinical Trial Update: Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels [Phase 4]
A Phase 4 trial is comparing standard-dose alectinib to dose-adjusted dosing based on blood levels in ALK-positive non-small cell lung cance…
-
CLINICAL_TRIALS trial_result · 2024-05-10Clinical Trial Update: A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis
A retrospective study evaluating the efficacy and safety of Lolatinib in ALK-positive non-small cell lung cancer patients with brain metasta…
-
CLINICAL_TRIALS trial_result · 2024-04-26Clinical Trial Update: Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib [Phase 2]
A Phase 2 trial of Alkotinib capsules in ALK-positive non-small cell lung cancer patients previously treated with Crizotinib has been termin…
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients
A completed clinical trial evaluating real-world outcomes of lorlatinib after alectinib in ALK-positive non-small-cell lung cancer patients …
-
FDA approval · 2021-09-24FDA Approved: ALUNBRIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for ALUNBRIG (brigatinib) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2013-09-13FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for XALKORI (crizotinib) submitted by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2013-02-28FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XALKORI (crizotinib) from Pfizer Laboratories Div Pfizer Inc.